SCHEMBL4185271

SCHEMBL4185271

Cc1ccc2c(N3CCN(C(=O)OC(C)(C)C)CC3)ccc(Cl)c2n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.44
KMT2A Q03164 3/20 0.44
MAPT P10636 2/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
CCNK O75909 1/20 0.44
CCNA2 P20248 1/20 0.44
CDK2 P24941 1/20 0.44
CCND3 P30281 1/20 0.44
CDK9 P50750 1/20 0.44
CDK6 Q00534 1/20 0.44
CNR1 P21554 1/20 0.44
CNR2 P34972 1/20 0.44
MAP4K4 O95819 1/20 0.43
POLB P06746 1/20 0.43
CKS1B P61024 1/20 0.43
SKP1 P63208 1/20 0.43
SKP2 Q13309 1/20 0.43
HTR1A P08908 1/20 0.42
HTR1D P28221 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2878919 0.86 MAP4K4 (0.43) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL30217575 0.85 CKS1B (0.44) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL25096858 0.85 CKS1B (0.44) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL4180873 0.84 HTR1A (0.46) MEN1KMT2AMAPTHTR1AHTR1D
SCHEMBL30217692 0.84 BACE1 (0.43) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL25096832 0.84 BACE1 (0.43) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL14686997 0.80 SMPD3 (0.49) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL430227 0.79 CYP2C9 (0.52) MEN1KMT2ACKS1BSKP1SKP2
SCHEMBL4009513 0.78 GRM5 (0.47) MEN1KMT2AMAPTTSHRSMN1; SMN2
SCHEMBL16040403 0.77 CKS1B (0.49) MEN1KMT2AMAPTTSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS GLAXO GROUP LIMITED 2009-03-19 US disclosed
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders GLAXO GROUP LIMITED (GB) 2006-11-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264429-A1 Benzoxazinone derivatives, preparation thereof and uses in the treatment of cns and other disorders XDH, CYP4X1, PDHX MEN1 2472/4885KMT2A 1509/4885MAPT 2057/4885
US-20090076274-A1 BENZOXAZINONE DERIVATIVES, PREPARATION THEREOF AND USES IN THE TREATMENT OF CNS AND OTHER DISORDERS XDH, CYP4X1, PDHX MEN1 1910/4885KMT2A 1832/4885MAPT 1924/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.